[{"id":"9480eee5-c88d-4aa5-a04a-bfe171590b90","acronym":"INCB 84344-102","url":"https://clinicaltrials.gov/study/NCT03934372","created_at":"2021-01-18T19:22:38.750Z","updated_at":"2025-02-25T14:40:12.243Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors","source_id_and_acronym":"NCT03934372 - INCB 84344-102","lead_sponsor":"Incyte Biosciences International Sàrl","biomarkers":" FLT3 • ABL1 • BCR • RET • FGFR • BLM","pipe":" | ","alterations":" EGFR mutation • KIT mutation • FGFR mutation • RET mutation","tags":["FLT3 • ABL1 • BCR • RET • FGFR • BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • KIT mutation • FGFR mutation • RET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Iclusig (ponatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/29/2020","start_date":" 01/29/2020","primary_txt":" Primary completion: 01/30/2026","primary_completion_date":" 01/30/2026","study_txt":" Completion: 01/30/2026","study_completion_date":" 01/30/2026","last_update_posted":"2025-02-14"},{"id":"a68c3584-e015-40fa-9ded-0ebfc3f5e6c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03825367","created_at":"2021-01-18T18:53:35.582Z","updated_at":"2025-02-25T14:28:03.066Z","phase":"Phase 1/2","brief_title":"Nivolumab in Combination With 5-azacytidine in Childhood Relapsed/Refractory AML","source_id_and_acronym":"NCT03825367","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" BLM","pipe":"","alterations":" ","tags":["BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • azacitidine"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 11/29/2019","start_date":" 11/29/2019","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 03/30/2024","study_completion_date":" 03/30/2024","last_update_posted":"2022-10-11"},{"id":"56bf1de6-4149-4ce1-9e77-9b290066ee12","acronym":"","url":"https://clinicaltrials.gov/study/NCT03263936","created_at":"2021-01-18T16:07:26.214Z","updated_at":"2024-07-02T16:36:08.325Z","phase":"Phase 1","brief_title":"Epigenetic Reprogramming in Relapse/Refractory AML","source_id_and_acronym":"NCT03263936","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" BLM","pipe":"","alterations":" ","tags":["BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • decitabine • Zolinza (vorinostat) • fludarabine IV • Neupogen (filgrastim)"],"overall_status":"Completed","enrollment":" Enrollment 37","initiation":"Initiation: 07/11/2017","start_date":" 07/11/2017","primary_txt":" Primary completion: 07/09/2020","primary_completion_date":" 07/09/2020","study_txt":" Completion: 02/10/2022","study_completion_date":" 02/10/2022","last_update_posted":"2022-06-24"},{"id":"8c3f0361-796d-4885-a0b8-e4b7e531993d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01861002","created_at":"2021-01-18T08:19:13.965Z","updated_at":"2024-07-02T16:36:29.375Z","phase":"Phase 1","brief_title":"A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML","source_id_and_acronym":"NCT01861002","lead_sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","biomarkers":" BLM","pipe":"","alterations":" ","tags":["BLM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • azacitidine • fludarabine IV"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 05/22/2013","start_date":" 05/22/2013","primary_txt":" Primary completion: 07/28/2014","primary_completion_date":" 07/28/2014","study_txt":" Completion: 07/28/2014","study_completion_date":" 07/28/2014","last_update_posted":"2021-06-09"}]